Daiichi Sankyo Exercises Option With Aussie Biotech Biota For Second-Gen Flu Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Biota would get royalties on Japanese sales and share rest-of-world commercialization rights 50/50 with Daiichi.